Table 3.

Vaccination coverage in the repeat survey, human papillomavirus prevalence, and overall vaccine effectiveness for HPV types 6, 11, 16, and 18 by age, level of education, and HIV status

	Baseline survey			Repeat survey				Adjusted vaccine effectiveness (95% CI)*
	Number assessed	HPV-positive	HPV prevalence (95% CI)†	Vaccination coverage	Number assessed	HPV-positive	HPV prevalence (95% CI)†
Age 17–23 years
<6 years of school	479	52	11% (8 to 14)	23%	358	29	8% (6 to 11)	16% (−34 to 47)
≥6 years of school	613	82	13% (11 to 16)	63%	812	33	4% (3 to 6)	68% (51 to 79)
HIV-negative	754	75	10% (8 to 12)	52%	1072	52	5% (4 to 6)	55% (36 to 69)
HIV-positive	115	19	17% (10 to 25)	31%	93	10	11% (5 to 19)	24% (−62 to 64)
Age 24–29 years
<6 years of school	167	20	12% (8 to 18)	1%	161	10	6% (3 to 11)	54% (−3 to 79)
≥6 years of school	242	19	8% (5 to 12)	14%	274	16	6% (3 to 9)	25% (−45 to 61)
HIV-negative	272	25	9% (6 to 13)	11%	341	12	4% (2 to 6)	55% (12 to 78)
HIV-positive	66	9	14% (6 to 24)	2%	97	13	13% (7 to 22)	−17% (−172 to 50)

Data are n or % unless otherwise stated. HPV=human papillomavirus.

^*Overall vaccine effectiveness adjusted for level of education, HIV status, and lifetime number of sexual partners.

^†Crude prevalence.